Drug-induced QT prolongation

Lore & Background

QT prolongation is a measure of delayed ventricular repolarisation, meaning the heart muscle takes longer than normal to recharge between beats. On an EKG, the QT interval represents the summation of action potentials in cardiac muscle cells. Prolongation can be caused by an increase in inward current through sodium or calcium channels, or a decrease in outward current through potassium channels. Certain drugs bind to and inhibit the 'rapid' delayed rectifier potassium current protein (IKr, encoded by the hERG gene), decreasing outward potassium flow and extending phase 3 myocardial repolarization.

Risk factors for developing drug-induced QT prolongation include increasing dose, rapid infusion, concurrent use of more than one QT-prolonging drug, diuretic treatment, electrolyte derangements (hypokalemia, hypomagnesemia, hypocalcemia), advanced age, bradyarrhythmias, and female sex. TdP occurs up to three times more often in females, likely due to post-pubertal hormonal influence: estrogens prolong the QT interval, while androgens shorten it. Structural heart disease such as heart failure, myocardial infarction, and left ventricular hypertrophy are also risk factors.

Drugs that cause QT prolongation include antiarrhythmic agents (Class IA and III), psychiatric medications (typical and atypical antipsychotics, SSRIs, SNRIs, tricyclic antidepressants), antibiotics (macrolides, fluoroquinolones), and other agents such as methadone, ondansetron, chloroquine, and tamoxifen. The risk of TdP varies and is often stratified by known, possible, or conditional risk. Some drugs reduce trafficking of the hERG protein to the cell surface rather than directly blocking the channel.

Reader's Guide

Drug-induced QT prolongation is a significant clinical concern because it can lead to torsades de pointes, a potentially fatal arrhythmia. The condition arises from a wide variety of medications, including those used for common conditions such as infections, depression, and allergies. Understanding risk factors—such as female sex, electrolyte imbalances, and concurrent use of multiple QT-prolonging drugs—is essential for prevention. The FDA provides guidance on QTc prescription drug labeling to help clinicians assess risk. While many cases of TdP self-resolve, the arrhythmia can degenerate into ventricular fibrillation and cause sudden cardiac death. Awareness of this side effect has led to the withdrawal of some drugs (e.g., thioridazine) and careful monitoring of others. The pathophysiology primarily involves blockade of the IKr potassium channel encoded by the hERG gene, though some drugs impair channel trafficking. This knowledge informs drug development and clinical prescribing practices, emphasizing the need for EKG monitoring in at-risk patients, especially those on high doses or multiple QT-prolonging agents.

Did You Know?

• Torsades de pointes translates from French as 'twisting of the peaks' because the QRS complexes appear to undulate around the EKG baseline.
• TdP occurs up to three times more often in female patients compared with males, likely due to post-pubertal hormonal influence on cardiac ion channels.
• Some drugs that cause QT prolongation do not directly block hERG but reduce trafficking of the mature protein to the cell surface.
• Amiodarone causes QT prolongation but torsades de pointes is rarely observed, despite its multiple channel-blocking actions.

The Electrical Story Behind a Lengthened Interval

The QT interval, measured on an electrocardiogram from the onset of the Q wave to the terminus of the T wave, captures the total time a ventricle needs to contract and then fully relax before the next beat. At the cellular level, this interval reflects the combined action potentials of cardiac muscle cells. When a drug interferes with the delicate balance of ion currents—either by boosting inward sodium or calcium flow or, more commonly, by suppressing outward potassium flow—the repolarization phase stretches beyond its normal duration. The most well-characterized mechanism involves a drug binding to and inhibiting the protein responsible for the rapid delayed rectifier potassium current. With that outward potassium pathway blocked, phase three of myocardial repolarization is prolonged, and the QT interval lengthens on the tracing. What begins as a subtle electrical delay can, if severe enough, set the stage for dangerous tachycardias. The condition is not limited to heart medications; antibiotics, antidepressants, antipsychotics, antihistamines, opioids, and even complementary medicines have all been implicated as triggers.

Torsades de Pointes: When the Heart Twists

Among the most feared consequences of a drug-induced lengthened QT interval is torsades de pointes, a polymorphic ventricular tachycardia whose name comes from the French phrase meaning "twisting of the peaks." On an electrocardiogram, the rapid and irregular QRS complexes appear to undulate around the baseline, giving the rhythm its evocative name. During an episode, the heart races at two hundred to two hundred and fifty beats per minute, and the patient may experience palpitations or lose consciousness entirely. While many TdP episodes resolve on their own, the arrhythmia can deteriorate into ventricular fibrillation, which carries the risk of sudden cardiac death. TdP can arise from an inherited congenital long QT syndrome, but the more common trigger is the ingestion of a pharmacologic agent. The diagnosis is confirmed through EKG findings, and the condition underscores why even a seemingly routine medication can become life-threatening when it disrupts the heart's electrical timing.

Who Is Most Vulnerable? Risk Factors and Hormonal Influence

Predicting exactly which patient will develop drug-induced QT prolongation remains difficult, yet several consistent risk factors have emerged. Higher doses of an offending agent increase the likelihood of a prolonged interval, and administering a drug by rapid infusion compounds the danger. Taking more than one QT-prolonging medication simultaneously, having electrolyte imbalances such as low potassium, magnesium, or calcium, and being in advanced age all elevate risk. Female sex stands out as a particularly important factor: torsades de pointes occurs up to three times more frequently in women than in men. This disparity is largely attributed to post-pubertal hormonal effects on cardiac ion channels. Estrogens tend to lengthen the QT interval, while testosterone upregulates the rapid delayed rectifier potassium channels, effectively shortening the interval and blunting the response to IKr-blocking drugs. Structural heart conditions—heart failure, prior myocardial infarction, left ventricular hypertrophy—further compound vulnerability, as diuretic-induced electrolyte losses and ischemic damage can each independently provoke proarrhythmic events.

The Drug Classes Most Likely to Prolong the QT Interval

Several therapeutic categories carry a well-documented association with QT prolongation. Among antiarrhythmics, Class IA agents such as quinidine, procainamide, disopyramide, and propafenone block both sodium and potassium channels; at therapeutic concentrations the potassium-blocking effect dominates, making torsades de pointes a recognized complication, particularly with quinidine. Class III agents are dedicated potassium channel blockers, yet they behave differently: amiodarone, with its multi-channel and adrenergic receptor activity, prolongs the QT interval but rarely triggers TdP, whereas sotalol—carrying beta-blocking properties—produces proarrhythmia in roughly two to seven percent of patients taking three hundred twenty milligrams or more per day. Ibutilide takes a distinct approach by activating slow inward sodium channels rather than inhibiting outward potassium flow. Beyond cardiology, antipsychotics like haloperidol (which blocks the KCNH2 channel), antidepressants, antibiotics, antivirals, antifungals, antihistamines, opioids, and complementary medicines all appear on the list of potential culprits. The FDA stratifies these agents into known, possible, and conditional risk categories to guide prescribing decisions.